Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Charu Aggarwal(UPMC Hillman Cancer Center), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Ezio Bonvini(MacroGenics (United States)), Vinod Ganju(Peninsula Health), Paul A. Moore(Zymeworks (Canada)), Rosetta Cavallo(MacroGenics (United States)), Dan P. Zandberg(University of Pittsburgh Medical Center), Yanyan Lou(WinnMed), Ralph J. Hauke(Canadian Cancer Society), Jan Baughman(University of California System), Linda Peng(MacroGenics (United States)), Andrew Weickhardt(Austin Hospital), Scott Antonia(Parker Institute for Cancer Immunotherapy), S. Goldberg(MacroGenics (United States)), Amy Prawira(St Vincent's Hospital Sydney), Sanjeev Kaul(AstraZeneca (United States)), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Mahesh Seetharam(Mayo Clinic in Arizona), Osama E. Rahma(Dana-Farber/Harvard Cancer Center), Anthony M. Joshua(St Vincent's Hospital Sydney), Robert L. Ferris(University of Pittsburgh), Fernanda I. Arnaldez(MacroGenics (United States)), Xiaoyu Zhang(Minzu University of China), Ariel E. Birnbaum(Rhode Island Hospital), Roger B. Cohen(University of Pennsylvania), Victoria Atkinson(Greenslopes Private Hospital), Alex A. Adjei(Cleveland Clinic), Arash Rezazadeh Kalebasty(University of California, Irvine)

Journal for ImmunoTherapy of Cancer

April 1, 2022

Cited by 140

|New England Journal of Medicine|2012|12.6k

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2014|5.3k

|New England Journal of Medicine|2016|5.1k

|New England Journal of Medicine|2017|3.4k

Related Papers